UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
1.
Full Text
The Silver Lining to COVID-19: Avoiding Diabetic Ketoacidosis Admissions with Telehealth
Diabetes technology & therapeutics, ISSN 1520-9156, 06/2020, Volume 22, Issue 6, pp. 449 - 453
Improving Access with Telehealth and CGM During COVID-19 and Beyond | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Coronavirus Infections - prevention & control | California - epidemiology | Humans | Pandemics - prevention & control | Male | Hospitalization | Diabetes Mellitus, Type 1 - complications | Diabetic Ketoacidosis - therapy | COVID-19 | Young Adult | Blood Glucose Self-Monitoring - methods | SARS-CoV-2 | Hypoglycemic Agents - administration & dosage | Pneumonia, Viral - prevention & control | Pneumonia, Viral - complications | Telemedicine - methods | Betacoronavirus | Coronavirus Infections - complications | Adult | Diabetic Ketoacidosis - prevention & control | Female | Colorado - epidemiology | Pandemics | Diabetes | Coronaviruses | Telemedicine | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2012, Volume 379, Issue 9825, pp. 1489 - 1497
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | General aspects | Diabetes. Impaired glucose tolerance | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Glycated Hemoglobin A - analysis | Drug Administration Schedule | Humans | Male | Diabetes Mellitus, Type 1 - drug therapy | Insulin, Long-Acting - adverse effects | Insulin Aspart - administration & dosage | Insulin, Long-Acting - administration & dosage | Hypoglycemic Agents - administration & dosage | Insulin Glargine | Diabetes Mellitus, Type 1 - blood | Insulin, Long-Acting - therapeutic use | Adult | Female | Hypoglycemic Agents - adverse effects | Dosage and administration | Diagnosis | Drug therapy | Type 1 diabetes | Insulin | Committees | Public speaking | Product development | Diabetes | Clinical medicine | Pharmaceutical industry | Index Medicus | Abridged Index Medicus | Side effects | Hospitals | complications | insulin | Risk reduction | diabetes mellitus | Stratification | Life Sciences | Hypoglycemic Agents | Insulin Aspart | Insulin, Long-Acting | Hemoglobin A, Glycosylated | Diabetes Mellitus, Type 1
Journal Article
Diabetes technology & therapeutics, ISSN 1520-9156, 02/2020, Volume 22, Issue S1, pp. S-1 - S-1
Journal Article
Diabetes technology & therapeutics, ISSN 1520-9156, 02/2020, Volume 22, Issue 2, pp. 63 - 65
Journal Article
Diabetes technology & therapeutics, ISSN 1520-9156, 10/2017, Volume 19, Issue 10, pp. 549 - 551
Journal Article
The Lancet (British edition), ISSN 0140-6736, 11/2017, Volume 390, Issue 10110, pp. 2329 - 2331
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Pregnancy | Studies | Hyperglycemia | Womens health | Diabetes mellitus | Diabetes | Sensors | Glucose | Hypoglycemia | Insulin | Endocrinology | Health care | Neonates | Risk | Population studies | Infants | Diabetes mellitus (insulin dependent) | Electronic implants | Gestational age | Population | Monitoring | Risk groups | Fetuses | Real time | Patients | Babies | Government programs | Ketoacidosis | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes technology & therapeutics, ISSN 1520-9156, 02/2018, Volume 20, Issue S1, pp. S-1 - S-1
Journal Article
Diabetes technology & therapeutics, ISSN 1520-9156, 02/2019, Volume 21, Issue S1, pp. S-1 - S-2
Journal Article
Diabetes technology & therapeutics, ISSN 1520-9156, 02/2021
Journal Article
The New England journal of medicine, ISSN 0028-4793, 07/2013, Volume 369, Issue 3, pp. 224 - 232
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | General aspects | Medical sciences | Blood Glucose - analysis | Area Under Curve | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Insulin Infusion Systems - adverse effects | Insulin - administration & dosage | Male | Diabetes Mellitus, Type 1 - drug therapy | Hypoglycemia - prevention & control | Young Adult | Hypoglycemic Agents - administration & dosage | Diabetes Mellitus, Type 1 - blood | Adolescent | Adult | Female | Aged | Hypoglycemia - chemically induced | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Prevention | Care and treatment | Insulin pumps | Research | Diabetes | Hypoglycemia | Health aspects | Automation | Diabetes mellitus | Diabetes mellitus (insulin dependent) | Glucose | Insulin | Quality of life | Studies | Ketoacidosis | Hemoglobin | Software | Sensors | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes technology & therapeutics, ISSN 1520-9156, 02/2019, Volume 21, Issue 2, pp. 66 - 72
Original Articles | Continuous glucose monitor use | T1D Exchange registry | Insulin pump use | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Hypoglycemic Agents - therapeutic use | United States | Humans | Middle Aged | Child, Preschool | Blood Glucose | Insulin - administration & dosage | Male | Diabetes Mellitus, Type 1 - drug therapy | Young Adult | Hypoglycemic Agents - administration & dosage | Diabetes Mellitus, Type 1 - blood | Adolescent | Adult | Female | Insulin Infusion Systems | Registries | Aged | Disease Management | Child | Insulin - therapeutic use | Datasets | Pediatrics | Glucose monitoring | Adults | Diabetes | Disease management | Trends | Age | Clinical outcomes | Original
Journal Article
The New England journal of medicine, ISSN 0028-4793, 12/2017, Volume 377, Issue 24, pp. 2337 - 2348
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Glycated Hemoglobin A - analysis | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Humans | Middle Aged | Diabetic Ketoacidosis - etiology | Male | Diabetes Mellitus, Type 1 - drug therapy | Young Adult | Diabetes Mellitus, Type 1 - blood | Adolescent | Intention to Treat Analysis | Least-Squares Analysis | Adult | Female | Glycosides - adverse effects | Diabetic Ketoacidosis - epidemiology | Sodium-Glucose Transport Proteins - antagonists & inhibitors | Drug Therapy, Combination | Hypoglycemia - chemically induced | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Glycosides - therapeutic use | Insulin - therapeutic use | Treatment outcome | Control | Care and treatment | Blood sugar | Type 1 diabetes | Analysis | Hypoglycemic agents | Dosage and administration | Drug therapy | Diabetes mellitus | Glucose | Hypoglycemia | Insulin | Sodium | Ketoacidosis | Patient safety | Hemoglobin | Blood pressure | Diabetes | Drug dosages | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes technology & therapeutics, ISSN 1520-9156, 02/2016, Volume 18, Issue S2, pp. S2-iv - S2-2
Editorial | Continuous Glucose Monitoring | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Diabetes Mellitus - blood | Monitoring, Ambulatory - trends | Blood Glucose - analysis | Blood Glucose Self-Monitoring - trends | Monitoring, Ambulatory - methods | Humans | Forecasting | Index Medicus
Journal Article
Diabetes care, ISSN 0149-5992, 2017, Volume 40, Issue 12, pp. 1631 - 1640
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Hypoglycemic Agents - therapeutic use | Blood Glucose Self-Monitoring - standards | Physicians | Glycated Hemoglobin A - metabolism | Humans | Clinical Trials as Topic | Hypoglycemia - drug therapy | Hyperglycemia - drug therapy | Consensus | Diabetes Mellitus, Type 1 - drug therapy | Diabetes Mellitus, Type 2 - blood | Reference Standards | Hyperglycemia - blood | International Agencies | Research Personnel | Diabetes Mellitus, Type 1 - blood | Hypoglycemia - blood | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Insulin - therapeutic use | Usage | Control | Care and treatment | Diabetes | Glucose monitors | Blood sugar | Medical personnel | Hyperglycemia | Complications | Diabetes mellitus | Hemoglobin | Data processing | Microvasculature | Glucose | Hypoglycemia | Monitoring | Index Medicus | Life Sciences | Continuous Glucose Monitoring and Risk of Hypoglycemia | 0301
Journal Article
Diabetes technology & therapeutics, ISSN 1520-9156, 02/2017, Volume 19, Issue S1, pp. S-1 - S-1
ATTD 2016 Yearbook | Editorials | Advanced Technologies & Treatments for Diabetes | Edited by Moshe Phillip and Tadej Battelino | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Leadership | Anniversaries and Special Events | Diabetes Mellitus - therapy | Humans | Therapies, Investigational - trends | Diffusion of Innovation | Biomedical Research - methods | Biomedical Research - trends | Periodicals as Topic | Index Medicus
Journal Article